RNA Outsourcing Articles

1. The Delivery Challenge For In Vivo Cell Engineering 7/30/2026

   As RNA therapies expand beyond the liver, delivery—not payload design—has become the defining challenge for precise, scalable in vivo cell engineering.

2. Soliman Says… 5 Questions Every RNA Platform Must Answer Before Investors Write The Check 7/21/2026

   A practical framework for evaluating whether an RNA company has the science, strategy, scalability, and discipline to become a lasting platform.

3. Bridging The Atlantic: A European Executive's Guide To Entering The U.S. RNA Market (Pt. 1) 7/13/2026

   A practical roadmap for European biotech leaders navigating FDA expectations, market entry, and the strategic decisions that shape U.S. expansion.

4. The Hidden Bottleneck In Advanced Therapies Isn't Science… It's Translational Friction 6/26/2026

   Scientific breakthroughs may spark innovation, but operational excellence ultimately determines which advanced therapies reach patients.

5. RNA Therapeutics: Why CMC Strategy Will Define The Next Decade 6/25/2026

   As RNA matures into an industrial platform, long-term success will depend less on discovery and more on scalable CMC systems, integration, and execution.

6. How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation 3/19/2026

   Subtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.

7. 2026 RNA Investment Landscape: Recent Deals, IPOs, And Venture Trends 2/22/2026

   As RNA investing matures, capital is flowing toward delivery, durability, and regulatory credibility. This column breaks down the deals, IPO signals, and venture theses shaping RNA’s 2026 winners—and why.

8. A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026? 1/30/2026

   In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.

9. Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026 12/16/2025

   Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond. 

10. Four Reasons You Should Choose Lyophilization for Your Next Project 12/10/2025

    Lyophilization ensures product stability, extends shelf life, supports sensitive formulations, and simplifies storage and transport, making it a critical choice for modern drug development projects.